We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+22.23%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$20B
AUM Growth
+$2.54B
Cap. Flow
+$128M
Cap. Flow %
0.64%
Top 10 Hldgs %
72.82%
Holding
92
New
8
Increased
16
Reduced
7
Closed
9

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$276M
2
INSM icon
Insmed
INSM
+$166M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$32.6M
4
FTH
Faeth Therapeutics
FTH
+$29.8M
5
RLAY icon
Relay Therapeutics
RLAY
+$24.2M

Top Sells

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$99.1M
2
ABVX
Abivax
ABVX
+$97.5M
3
SMMT icon
Summit Therapeutics
SMMT
+$63.9M
4
SYRE icon
Spyre Therapeutics
SYRE
+$50.4M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$26.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Miscellaneous 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLUE icon
26
Monte Rosa Therapeutics
GLUE
$1.14B
$105M 0.53%
4,345,736
– –
IMTX icon
27
Immatics
IMTX
$1.44B
$96.3M 0.48%
9,508,565
-1,408,128
-13% -$14.9M
DNLI icon
28
Denali Therapeutics
DNLI
$3.84B
$96M 0.48%
3,734,336
+2,641
+0.1% +$54.3K
CRNX icon
29
Crinetics Pharmaceuticals
CRNX
$9B
$88M 0.44%
2,351,465
– –
DNTH icon
30
Dianthus Therapeutics
DNTH
$5.92B
$83.1M 0.42%
852,164
– –
GPCR icon
31
Structure Therapeutics
GPCR
$3.38B
$76.9M 0.39%
1,432,529
– –
RAPP
32
Rapport Therapeutics
RAPP
$2.34B
$64.5M 0.32%
1,547,090
– –
ALMS
33
Alumis Inc
ALMS
$2.9B
$56.6M 0.28%
2,012,500
– –
PRLD icon
34
Prelude Therapeutics
PRLD
$437M
$54M 0.27%
10,123,824
– –
RLAY icon
35
Relay Therapeutics
RLAY
$4.11B
$52.9M 0.27%
2,826,783
+1,666,666
+144% +$24.2M
MIRM icon
36
Mirum Pharmaceuticals
MIRM
$5.94B
$52.2M 0.26%
445,975
– –
BCYC
37
Bicycle Therapeutics
BCYC
$294M
$46.2M 0.23%
10,885,357
– –
ELVN icon
38
Enliven Therapeutics
ELVN
$4.24B
$45.9M 0.23%
905,191
– –
CLDX icon
39
Celldex Therapeutics
CLDX
$3.07B
$44M 0.22%
1,182,611
+517,241
+78% +$16.7M
VRDN icon
40
Viridian Therapeutics
VRDN
$2.61B
$43.8M 0.22%
2,383,025
+411,347
+21% +$6.63M
DSGN icon
41
Design Therapeutics
DSGN
$946M
$38.8M 0.19%
2,678,430
+92,452
+4% +$1.15M
TRDA icon
42
Entrada Therapeutics
TRDA
$273M
$37.3M 0.19%
5,072,730
– –
FTH
43
Faeth Therapeutics
FTH
$874M
$32.2M 0.16%
+1,286,411
New +$29.8M
AKTS
44
Aktis Oncology
AKTS
$1.43B
$32.1M 0.16%
996,351
– –
NGNE icon
45
Neurogene
NGNE
$732M
$31.2M 0.16%
991,691
– –
JBIO
46
Jade Biosciences
JBIO
$1.33B
$27.3M 0.14%
1,230,426
-410,711
-25% -$8.57M
TSHA icon
47
Taysha Gene Therapies
TSHA
$1.88B
$27.3M 0.14%
4,004,756
– –
RCUS icon
48
Arcus Biosciences
RCUS
$3.72B
$26M 0.13%
844,816
+429,195
+103% +$10.6M
IRON icon
49
Disc Medicine
IRON
$3.07B
$25.6M 0.13%
349,657
– –
ABSI icon
50
Absci
ABSI
$1.49B
$24.7M 0.12%
2,134,803
– –
1
2
3 4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Baker Bros. Advisors held 92 positions worth $20B, up 15% from $17.4B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors's Q2 2026 filing shows 8 new, 16 increased, 7 reduced and 9 closed positions. Its largest new stake was Faeth Therapeutics: 1,286,411 shares worth $32.2M. The largest sale was Edgewise Therapeutics, an estimated $99.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • Baker Bros. Advisors's largest Q2 2026 buy was Faeth Therapeutics: 1,286,411 shares worth $32.2M.
  • Baker Bros. Advisors added most to Revolution Medicines in Q2 2026, an estimated $276M increase.
  • Baker Bros. Advisors's biggest Q2 2026 reduction was Edgewise Therapeutics, cutting an estimated $99.1M.
  • Baker Bros. Advisors fully exited Abivax in Q2 2026, selling an estimated $97.5M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $20B portfolio in Q2 2026.
  • Baker Bros. Advisors opened 8 new positions and closed 9 in Q2 2026.
  • Baker Bros. Advisors's portfolio value rose 15% quarter-over-quarter to $20B.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.